Clinic of Dermatovenereology, Clinical Center of Serbia, Belgrade, Serbia.
Department of Dermatovenereology, School of Medicine, University of Belgrade, Belgrade, Serbia.
Dermatol Ther. 2020 Jan;33(1):e13152. doi: 10.1111/dth.13152. Epub 2019 Nov 19.
We present a patient with a 33-year history of poikilodermatous mycosis fungoides (MF) who subsequently developed CD30-positive large cell transformation. After 6 years of conventional MF treatment, side effects of therapy and/or concomitant diseases prevented the previously applied treatment modalities. The CD30-directed antibody-cytotoxic drug conjugate (brentuximab vedotin) was introduced and followed by quick and excellent therapeutic response.
我们报告了一例患有斑状蕈样肉芽肿（MF）33 年病史的患者，随后发展为 CD30 阳性的大细胞转化。经过 6 年的常规 MF 治疗，治疗的副作用和/或并存疾病使先前应用的治疗方法无法进行。引入了靶向 CD30 的抗体-细胞毒性药物偶联物（ Brentuximab vedotin），随后迅速产生了极好的治疗反应。
